Building on their recent research focusing on a peptide designed to block the oxidant amplifying function of the cellular sodium-potassium pump, researchers have successfully demonstrated that pNaKtide, can attenuate the development of experimental nonalcoholic fatty liver disease (NAFLD) and atherosclerosis.